ProjectEnhancing access to oncology medicines in Sub-Saharan Africa
Cancer is an emerging healthcare challenge in Sub-Saharan Africa. Compared to communicable diseases – such as HIV/AIDS, malaria and polio – cancer has not received its due share of attention.
The African population is expected to climb to 1.3 billion, at par with China, by 2020. At the same time, per-capita spending on pharmaceuticals is expected to more than double, from currently US$17.4 to about US$40.
Yet, it is very challenging for the patients to receive cancer treatments. In most Sub-Saharan countries, the availability of cancer diagnostic facilities is scarce. These countries often also lack medical expertise in oncology. This is accentuated by a lack of disease awareness and adherence to treatment when available. Governments are currently not able to prioritize cancer treatment and their expertise in biologics remains limited. Furthermore, there is also lack of local prevalence data, uncertainties regarding supply chain quality, and limited funding to healthcare in general.
Endeva, in cooperation with 3xBL and BroadReach Corporation, was appointed by a large global pharmaceutical company to develop strategies for improving access to oncology treatment in Sub-Saharan countries through a commercially viable business model.
Throughout the project we adopted a patient-centric approach focusing on the 6A’s framework – awareness, adherence, acceptability / appeal, affordability, availability and alliances with other stakeholders. We undertook an extensive analysis of the existing landscape in three pilot countries, Kenya, Nigeria and Senegal. Some of the themes of this analysis included:
- Patient journeys from cancer detection to treatment
- Landscape of existing healthcare providers including hospitals and cancer centres
- Payment mechanisms used by patients to pay for treatment
- Role of governments in healthcare systems and other key stakeholders such as insurance companies and NGOs among others
This analysis took into account the perspectives from several of the pharma company's staff on the ground.
We developed initial blue prints of a business model which addressed the four major issue areas identified during the analysis phase: fulfilment, patient education, identification and navigation. We also identified important knowledge gaps to be filled before the business model is implemented.